Summary
166.44 2.09(1.27%)05/17/2024
Abbvie Inc (ABBV)
Abbvie Inc (ABBV)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.22 | -1.86 | -4.90 | -7.12 | 15.99 | 12.11 | 155.61 | 616.99 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 160.75 | |
| Open | 160.71 | |
| High | 161.44 | |
| Low | 160.35 | |
| Volume | 3,509,603 | |
| Change | 0.35 | |
| Change % | 0.22 | |
| Avg Volume (20 Days) | 5,205,206 | |
| Volume/Avg Volume (20 Days) Ratio | 0.67 | |
| 52 Week Range | 130.96 - 182.89 | |
| Price vs 52 Week High | -12.11% | |
| Price vs 52 Week Low | 22.75% | |
| Range | 0.02 | |
| Gap Up/Down | -0.61 | |
Fundamentals | ||
| Market Capitalization (Mln) | 293,876 | |
| EBIDTA | 26,115,999,744 | |
| PE Ratio | 47.8423 | |
| PEG Ratio | 0.4488 | |
| WallStreet Target Price | 182.41 | |
| Book Value | 4.5350 | |
| Earnings Per Share | 3.3600 | |
| EPS Estimate Current Quarter | 2.2300 | |
| EPS Estimate Next Quarter | 2.8100 | |
| EPS Estimate Current Year | 11.2600 | |
| EPS Estimate Next Year | 12.0700 | |
| Diluted EPS (TTM) | 3.3600 | |
| Revenues | ||
| Profit Marging | 0.1102 | |
| Operating Marging (TTM) | 0.2829 | |
| Return on asset (TTM) | 0.0771 | |
| Return on equity (TTM) | 0.5624 | |
| Revenue TTM | 54,402,998,272 | |
| Revenue per share TTM | 30.7750 | |
| Quarterly Revenue Growth (YOY) | 0.0070 | |
| Quarterly Earnings Growth (YOY) | 4.9640 | |
| Gross Profit (TTM) | 41,527,000,000 | |
| Dividends | ||
| Dividend Share | 6.0600 | |
| Dividend Yield | 0.0386 | |
| Valuations | ||
| Trailing PE | 47.8423 | |
| Forward PE | 14.5773 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 27.7356 | |
| Revenue Enterprise Value | 6.1473 | |
| EBITDA Enterprise Value | 19.4450 | |
| Shares | ||
| Shares Outstanding | 1,765,869,952 | |
| Shares Float | 1,761,982,872 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 0.11 | |
| Institutions (%) | 72.44 | |
05/17 07:30 EST - prnewswire.com
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®
- AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD) - Data to be presented from the SEQUENCE head-to-head trial comparing risankizumab (SKYRIZI®) versus ustekinumab (STELARA®) in Crohn's disease include an economic analysis and oral presentation that assessed inflammation biomarkers - Additional presentations include efficacy and safety data evaluating clinical, endoscopic, and histologic outcomes from both the INSPIRE Phase 3 induction study and the COMMAND Phase 3 maintenance study of risankizumab as a therapy for adults with moderately to severely active ulcerative colitis NORTH CHICAGO, Ill. , May 17, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced it is presenting 15 abstracts at the 2024 Digestive Disease Week (DDW) Annual Meeting, being held May 18-21 in Washington, D.C.
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®
- AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD) - Data to be presented from the SEQUENCE head-to-head trial comparing risankizumab (SKYRIZI®) versus ustekinumab (STELARA®) in Crohn's disease include an economic analysis and oral presentation that assessed inflammation biomarkers - Additional presentations include efficacy and safety data evaluating clinical, endoscopic, and histologic outcomes from both the INSPIRE Phase 3 induction study and the COMMAND Phase 3 maintenance study of risankizumab as a therapy for adults with moderately to severely active ulcerative colitis NORTH CHICAGO, Ill. , May 17, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced it is presenting 15 abstracts at the 2024 Digestive Disease Week (DDW) Annual Meeting, being held May 18-21 in Washington, D.C.
05/17 07:11 EST - investorplace.com
7 Value Stocks to Buy and Hold for a Decade of Dominance
Finding equities with the potential for steady, long-term development is crucial. These seven prospects span a variety of industries and offer solid arguments for long-term investment.
7 Value Stocks to Buy and Hold for a Decade of Dominance
Finding equities with the potential for steady, long-term development is crucial. These seven prospects span a variety of industries and offer solid arguments for long-term investment.
05/16 12:45 EST - zacks.com
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?
05/16 06:00 EST - investorplace.com
Wall Street Favorites: 3 Retirement Stocks With Strong Buy Ratings for May 2024
What could be better than well-established retirement stocks to buy that you can trust? How about adding to that confidence level with the backing of Wall Street analysts.
Wall Street Favorites: 3 Retirement Stocks With Strong Buy Ratings for May 2024
What could be better than well-established retirement stocks to buy that you can trust? How about adding to that confidence level with the backing of Wall Street analysts.
05/15 17:50 EST - seekingalpha.com
AbbVie, Inc. (ABBV) Bank of America Health Care Conference Call Transcript
AbbVie, Inc. (NYSE:ABBV ) Bank of America Health Care Conference Call May 15, 2024 1:40 PM ET Company Participants Robert Michael - CEO Roopal Thakkar - SVP, Chief Medical Officer, Global Therapeutics Jeffrey Stewart - COO Conference Call Participants Geoffrey Meacham - Bank of America Merrill Lynch Operator Geoffrey Meacham With me on stage is CEO, Rob Michael, currently President and COO, I guess, but soon to be. Robert Michael Soon to be, yes.
AbbVie, Inc. (ABBV) Bank of America Health Care Conference Call Transcript
AbbVie, Inc. (NYSE:ABBV ) Bank of America Health Care Conference Call May 15, 2024 1:40 PM ET Company Participants Robert Michael - CEO Roopal Thakkar - SVP, Chief Medical Officer, Global Therapeutics Jeffrey Stewart - COO Conference Call Participants Geoffrey Meacham - Bank of America Merrill Lynch Operator Geoffrey Meacham With me on stage is CEO, Rob Michael, currently President and COO, I guess, but soon to be. Robert Michael Soon to be, yes.
05/15 15:37 EST - seekingalpha.com
2 Fortune 100 Best Co's To Work For Are Also Good To Own
2 Fortune 100 Best Co's To Work For Are Also Good To Own
2 Fortune 100 Best Co's To Work For Are Also Good To Own
2 Fortune 100 Best Co's To Work For Are Also Good To Own
05/14 13:10 EST - zacks.com
AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal
AbbVie (ABBV) inks an option-to-license and collaboration deal with Gilgamesh to develop next-generation therapies for psychiatric disorders.
AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal
AbbVie (ABBV) inks an option-to-license and collaboration deal with Gilgamesh to develop next-generation therapies for psychiatric disorders.
05/14 10:05 EST - zacks.com
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
05/14 08:10 EST - seekingalpha.com
My Dividend Stock Portfolio: New April Dividend Record - 101 Holdings With 22 Buys
Portfolio changes in April focus on BDCs, aiming to increase dividend income by at least $100 each month. Dividend income hit a new all-time record for April of $736, basically flat Y/Y and up 12% sequentially. Gifted Working Time 2024: Around 85 hours, or 10.6 days, of active work have been replaced with passive income in 2024, which is equivalent to more than two entire workweeks.
My Dividend Stock Portfolio: New April Dividend Record - 101 Holdings With 22 Buys
Portfolio changes in April focus on BDCs, aiming to increase dividend income by at least $100 each month. Dividend income hit a new all-time record for April of $736, basically flat Y/Y and up 12% sequentially. Gifted Working Time 2024: Around 85 hours, or 10.6 days, of active work have been replaced with passive income in 2024, which is equivalent to more than two entire workweeks.
05/14 08:00 EST - businesswire.com
Alzamend Neuro Announces Initial Closing of Private Placement
ATLANTA--(BUSINESS WIRE)---- $ABBV #15_Percent_Interest_Bearing_Preferred_Stock--Alzamend Neuro Announces Initial Closing of Private Placement; Investor Purchase Up to $25 Million of Preferred Shares; Proceeds for Clinical Trials.
Alzamend Neuro Announces Initial Closing of Private Placement
ATLANTA--(BUSINESS WIRE)---- $ABBV #15_Percent_Interest_Bearing_Preferred_Stock--Alzamend Neuro Announces Initial Closing of Private Placement; Investor Purchase Up to $25 Million of Preferred Shares; Proceeds for Clinical Trials.
05/14 06:30 EST - fool.com
3 Magnificent Stocks That Are Passive Income Machines
Eli Lilly is an ideal stock for growth and dividends. AbbVie is a Dividend King with a bright future.
3 Magnificent Stocks That Are Passive Income Machines
Eli Lilly is an ideal stock for growth and dividends. AbbVie is a Dividend King with a bright future.
05/13 11:09 EST - fool.com
What Is the Dividend Payout for AbbVie Stock?
AbbVie's best-selling product recently lost its patent protection, threatening the company's future results. The drugmaker's R&D pipeline, however, is more promising than it's getting credit for.
What Is the Dividend Payout for AbbVie Stock?
AbbVie's best-selling product recently lost its patent protection, threatening the company's future results. The drugmaker's R&D pipeline, however, is more promising than it's getting credit for.
05/13 08:39 EST - prnewswire.com
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
- Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders NORTH CHICAGO, Ill. and NEW YORK , May 13, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders.
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
- Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders NORTH CHICAGO, Ill. and NEW YORK , May 13, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders.
05/11 13:29 EST - businesswire.com
LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Landos Biopharma, Inc. (NasdaqCM: LABP) to AbbVie Inc. (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Landos will receive $20.42 in cash, plus one non-tradable contingent value right (with a value of up to $11.14 per share, subject to the achievement of a clinical development milest.
LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Landos Biopharma, Inc. (NasdaqCM: LABP) to AbbVie Inc. (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Landos will receive $20.42 in cash, plus one non-tradable contingent value right (with a value of up to $11.14 per share, subject to the achievement of a clinical development milest.
05/11 03:50 EST - fool.com
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
Novo Nordisk's Ozempic has changed the business entirely. Eli Lilly is a diversified giant with GLP-1 tailwinds.
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
Novo Nordisk's Ozempic has changed the business entirely. Eli Lilly is a diversified giant with GLP-1 tailwinds.
05/10 09:30 EST - fool.com
3 Rock-Solid Dividend Stocks That Are Ideal for Retirees
AbbVie is a diversified healthcare company that has been able to strengthen its portfolio via acquisitions. AT&T has faced a lot of negative press in recent years but its fundamentals remain sound.
3 Rock-Solid Dividend Stocks That Are Ideal for Retirees
AbbVie is a diversified healthcare company that has been able to strengthen its portfolio via acquisitions. AT&T has faced a lot of negative press in recent years but its fundamentals remain sound.
05/07 14:04 EST - investorplace.com
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Amid a challenging market environment, one of your best bets could be to target biotech stocks to buy. Yes, the sector can be volatile because much hinges on underlying breakthroughs.
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Amid a challenging market environment, one of your best bets could be to target biotech stocks to buy. Yes, the sector can be volatile because much hinges on underlying breakthroughs.
05/07 11:46 EST - marketbeat.com
AbbVie Tracking for New Highs in 2024
Shares of AbbVie NYSE: ABBV fell hard in the wake of its Q1 earnings report, but the dip is over. The market response to slowing Humira sales is overshadowed by strength in the non-Humira portfolio, resilient business, and a solid pipeline.
AbbVie Tracking for New Highs in 2024
Shares of AbbVie NYSE: ABBV fell hard in the wake of its Q1 earnings report, but the dip is over. The market response to slowing Humira sales is overshadowed by strength in the non-Humira portfolio, resilient business, and a solid pipeline.
05/06 08:00 EST - prnewswire.com
AbbVie to Present at the Bank of America Securities Healthcare Conference
NORTH CHICAGO, Ill. , May 6, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024.
AbbVie to Present at the Bank of America Securities Healthcare Conference
NORTH CHICAGO, Ill. , May 6, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024.